“Theranostics” in the management of prostate cancer

The word “theranostics” is a so-called “portmanteau” word made up from the words “therapeutics” and “diagnostics“. Thus, “theranostics” refers to the process of “diagnostic therapy” for individual patients. What exactly do we mean by this? … READ MORE …

Help with finding out about clinical trials for prostate cancer treatment

Apparently the National Cancer Institute (NCI) has just re-funded the Fred Hutchinson Cancer Research Center in Seattle to the tune of $24 million to continue to operate what we see as an important, patient-centric program here in the USA that we (and therefore probably many others) were utterly unaware of. … READ MORE …

Clinical and therapeutic histories of men who actually die of mCRPC

Despite all the prostate cancer research over the past 30 or so years, we still have limited information about the clinical and therapeutic history of prostate cancer in men who have progressive disease and go on to die of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Genomic/genetic tests for risk for clinically significant prostate cancer

The precise ability of the various genetic/genomic tests now available to accurately analyze the risk for clinically significant prostate cancer based on biopsy tissue samples is an important factor that all of the different developers and manufacturers of these tests continue to study in greater detail. … READ MORE …

ASCO’s new CancerLinQ initiative

As we move near to the annual meeting of the American Society of Clinical Oncology (ASCO) — which will start at the end of May in Chicago — ASCO has been making a lot of noise about its prototype CancerLinQ™ network. Just how valuable this will be for the future management of prostate cancer will take a while to work out. … READ MORE …

State of Victoria establishes regional prostate cancer registry (in Australia)

According to an article in BJU International, the State of Victoria, Australia, has initiated development of what appears to be a well-constructed, pilot, prostate cancer registry (PCR). Good for them! … READ MORE …

Long-term outcomes after RP as first-line therapy for men with cT3 disease at time of diagnosis

We have no data from randomized trials on the relative effectiveness of surgery compared to radiation therapy in the treatment of men initially diagnosed with clinical stage T3NxM0 prostate cancer. However, we do now have data from > 800 men treated with radical prostatectomy (RP) and followed for up to 23 years at the Mayo Clinic. … READ MORE …